![Placeholder Image Placeholder Image](https://prod.arctic.novartis.com/sites/novartis_com/files/placeholder.jpeg)
Tags Archive Navigation
icon
-
Media ReleaseNovartis announces positive results from Phase II study of LNP023 in patients with paroxysmal nocturnal hemoglobinuria (PNH)
-
Media ReleaseNovartis investigational novel STAMP inhibitor asciminib (ABL001) meets primary endpoint of Phase III chronic myeloid leukemia study
-
Media ReleaseNovartis new analysis shows high consistency in lowering LDL-C in individual response with investigational inclisiran
-
Media ReleaseNovartis post hoc analysis shows high-dose Enerzair® Breezhaler® reduces asthma exacerbations versus medium-dose, complementing key pivotal IRIDIUM study findings
-
StoryInspiring a daughter to make her own path
-
StoryReimagining asthma care: how data and digital could bring asthma management goals within reach
-
StoryMeet Manuel Cobos, transplant surgeon and researcher
-
StoryTalking to: Patrice Matchaba, Global Head of Corporate Responsibility for Novartis
-
StoryImproving lives through community-based care
-
StoryWomen in Science: Marjorie Eiref
-
StoryThree lessons I’ve learned as an industry postdoc
-
StoryReimagining protein sequencing
Pagination
- ‹ Previous page
- 1
- …
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- › Next page